Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Tests for time-to-event outcomes (survival analysis)

Similar presentations


Presentation on theme: "1 Tests for time-to-event outcomes (survival analysis)"— Presentation transcript:

1 1 Tests for time-to-event outcomes (survival analysis)

2 2 Time-to-event outcome (survival data) Outcome Variable Are the observation groups independent or correlated?Modifications to Cox regression if proportional- hazards is violated: independentcorrelated Time-to- event (e.g., time to fracture) Kaplan-Meier statistics: estimates survival functions for each group (usually displayed graphically); compares survival functions with log-rank test Cox regression: Multivariate technique for time-to-event data; gives multivariate-adjusted hazard ratios n/a (already over time) Time-dependent predictors or time- dependent hazard ratios (tricky!)

3 3 Early example of survival analysis, 1669 Christiaan Huygens' 1669 curve showing how many out of 100 people survive until 86 years. From: Howard Wainer­ STATISTICAL GRAPHICS: Mapping the Pathways of Science. Annual Review of Psychology. Vol. 52: 305-335

4 4 Early example of survival analysis Roughly, what shape is this function? What was a person’s chance of surviving past 20? Past 36? This is survival analysis! We are trying to estimate this curve—only the outcome can be any binary event, not just death.

5 5 What is survival analysis? Statistical methods for analyzing longitudinal data on the occurrence of events. Events may include death, injury, onset of illness, recovery from illness (binary variables) or transition above or below the clinical threshold of a meaningful continuous variable (e.g. CD4 counts). Accommodates data from randomized clinical trial or cohort study design.

6 Randomized Clinical Trial (RCT) Target population Intervention Control Disease Disease-free Disease Disease-free TIME Random assignment Disease-free, at-risk cohort

7 Target population Treatment Control Cured Not cured Cured Not cured TIME Random assignment Patient population Randomized Clinical Trial (RCT)

8 Target population Treatment Control Dead Alive Dead Alive TIME Random assignment Patient population Randomized Clinical Trial (RCT)

9 Cohort study (prospective/retrospective) Target population Exposed Unexposed Disease Disease-free Disease Disease-free TIME Disease-free cohort

10 10 Examples of survival analysis in medicine

11 11 RCT: Women’s Health Initiative (JAMA, 2001) On hormones On placebo Cumulative incidence

12 12 WHI and low-fat diet… Control Low-fat diet Prentice, R. L. et al. JAMA 2006;295:629-642.

13 13 Retrospective cohort study: From December 2003 BMJ: Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

14 14 Why use survival analysis? 1. Why not compare mean time-to-event between your groups using a t-test or linear regression? -- ignores censoring 2. Why not compare proportion of events in your groups using risk/odds ratios or logistic regression? --ignores time

15 15 Survival Analysis: Terms Time-to-event: The time from entry into a study until a subject has a particular outcome Censoring: Subjects are said to be censored if they are lost to follow up or drop out of the study, or if the study ends before they die or have an outcome of interest. They are counted as alive or disease-free for the time they were enrolled in the study.

16 16 Review Question 1 Which of the following data sets is likely to lend itself to survival analysis? a. A case-control study of caffeine intake and breast cancer. b. A randomized controlled trial where the outcome was whether or not women developed breast cancer in the study period. c. A cohort study where the outcome was the time it took women to develop breast cancer. d. A cross-sectional study which identified both whether or not women have ever had breast cancer and their date of diagnosis.

17 17 Introduction to Kaplan-Meier Non-parametric estimate of the survival function: Simply, the empirical probability of surviving past certain times in the sample (taking into account censoring).

18 18 Introduction to Kaplan-Meier Non-parametric estimate of the survival function. Commonly used to describe survivorship of study population/s. Commonly used to compare two study populations. Intuitive graphical presentation.

19 Beginning of studyEnd of study  Time in months  Subject B Subject A Subject C Subject D Subject E Survival Data (right-censored) 1. subject E dies at 4 months X

20 100%  Time in months  Corresponding Kaplan-Meier Curve Probability of surviving to 4 months is 100% = 5/5 Fraction surviving this death = 4/5 Subject E dies at 4 months

21 Beginning of studyEnd of study  Time in months  Subject B Subject A Subject C Subject D Subject E Survival Data 2. subject A drops out after 6 months 1. subject E dies at 4 months X 3. subject C dies at 7 months X

22 100%  Time in months  Corresponding Kaplan-Meier Curve subject C dies at 7 months Fraction surviving this death = 2/3

23 Beginning of studyEnd of study  Time in months  Subject B Subject A Subject C Subject D Subject E Survival Data 2. subject A drops out after 6 months 4. Subjects B and D survive for the whole year-long study period 1. subject E dies at 4 months X 3. subject C dies at 7 months X

24 24 100%  Time in months  Corresponding Kaplan-Meier Curve Rule from probability theory: P(A&B)=P(A)*P(B) if A and B independent In survival analysis: intervals are defined by failures (2 intervals leading to failures here). P(surviving intervals 1 and 2)=P(surviving interval 1)*P(surviving interval 2)  Product limit estimate of survival = P(surviving interval 1/at-risk up to failure 1) * P(surviving interval 2/at-risk up to failure 2) = 4/5 * 2/3=.5333

25 25 The product limit estimate The probability of surviving in the entire year, taking into account censoring = (4/5) (2/3) = 53% NOTE:  40% (2/5) because the one drop- out survived at least a portion of the year. AND <60% (3/5) because we don’t know if the one drop-out would have survived until the end of the year.

26 26 Example 1: time-to-conception for subfertile women “Failure” here is a good thing. 38 women (in 1982) were treated for infertility with laparoscopy and hydrotubation. All women were followed for up to 2-years to describe time-to-conception. The event is conception, and women "survived" until they conceived. Example from: BMJ, Dec 1998; 317: 1572 - 1580.

27 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored)

28 28 Corresponding Kaplan-Meier Curve S(t) is estimated at 9 event times. (step-wise function)

29 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored)

30 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored)

31 31 Corresponding Kaplan-Meier Curve 6 women conceived in 1 st month (1 st menstrual cycle). Therefore, 32/38 “survived” pregnancy-free past 1 month.

32 32 Corresponding Kaplan-Meier Curve S(t=1) = 32/38 = 84.2% S(t) represents estimated survival probability: P(T>t) Here P(T>1).

33 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12.1 13 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored) Important detail of how the data were coded: Censoring at t=2 indicates survival PAST the 2 nd cycle (i.e., we know the woman “survived” her 2 nd cycle pregnancy-free). Thus, for calculating KM estimator at 2 months, this person should still be included in the risk set. Think of it as 2+ months, e.g., 2.1 months.

34 34 Corresponding Kaplan-Meier Curve

35 35 Corresponding Kaplan-Meier Curve 5 women conceive in 2 nd month. The risk set at event time 2 included 32 women. Therefore, 27/32=84.4% “survived” event time 2 pregnancy-free. S(t=2) = ( 84.2%)*(84.4%)=71.1%

36 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12.1 13.1 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored) Risk set at 3 months includes 26 women

37 37 Corresponding Kaplan-Meier Curve

38 38 Corresponding Kaplan-Meier Curve S(t=3) = ( 84.2%)*(84.4%)*(88.5%)=62.8% 3 women conceive in the 3 rd month. The risk set at event time 3 included 26 women. 23/26=88.5% “survived” event time 3 pregnancy-free.

39 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13.1 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored) Risk set at 4 months includes 22 women

40 40 Corresponding Kaplan-Meier Curve

41 41 Corresponding Kaplan-Meier Curve S(t=4) = ( 84.2%)*(84.4%)*(88.5%)*(86.4%)=54.2% 3 women conceive in the 4 th month, and 1 was censored between months 3 and 4. The risk set at event time 4 included 22 women. 19/22=86.4% “survived” event time 4 pregnancy-free.

42 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13 14.1 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored) Risk set at 6 months includes 18 women

43 43 Corresponding Kaplan-Meier Curve

44 44 Corresponding Kaplan-Meier Curve S(t=6) = (54.2%)*(88.8%)=42.9% 2 women conceive in the 6 th month of the study, and one was censored between months 4 and 6. The risk set at event time 5 included 18 women. 16/18=88.8% “survived” event time 5 pregnancy-free.

45 45 Skipping ahead to the 9 th and final event time (months=16)… S(t=13)  22% (“eyeball” approximation)

46 Data from: Luthra P, Bland JM, Stanton SL. Incidence of pregnancy after laparoscopy and hydrotubation. BMJ 1982; 284: 1013-1014 Raw data: Time (months) to conception or censoring in 38 sub-fertile women after laparoscopy and hydrotubation (1982 study) 12 13 14 17 17 18 28 29 29 29 211 324 3 3 4 4 4 6 6 9 9 9 10 13 16 Conceived (event)Did not conceive (censored) 2 remaining at 16 months (9 th event time)

47 47 Skipping ahead to the 9 th and final event time (months=16)… S(t=16) =( 22%)*(2/3)=15% Tail here just represents that the final 2 women did not conceive (cannot make many inferences from the end of a KM curve)!

48 Comparing 2 groups Use log-rank test to test the null hypothesis of no difference between survival functions of the two groups

49 49 Kaplan-Meier: example 2 Researchers randomized 44 patients with chronic active hepatitis were to receive prednisolone or no treatment (control), then compared survival curves. Example from: BMJ 1998;317:468-469 ( 15 August )

50 Prednisolone (n=22)Control (n=22) 22 63 124 547 56 *10 6822 8928 9629 9632 125*37 128*40 131*41 140*54 141*61 14363 145*71 146127* 148*140* 162*146* 168158* 173*167* 181*182* Data from: BMJ 1998;317:468-469 ( 15 August ) *=censored Survival times (months) of 44 patients with chronic active hepatitis randomised to receive prednisolone or no treatment.

51 51 Kaplan-Meier: example 2 Are these two curves different? Misleading to the eye— apparent convergence by end of study. But this is due to 6 controls who survived fairly long, and 3 events in the treatment group when the sample size was small. Big drops at the end of the curve indicate few patients left. E.g., only 2/3 (66%) survived this drop.

52 52 Log-rank test Test of Equality over Strata Pr > Test Chi-Square DF Chi-Square Log-Rank 4.6599 1 0.0309 Chi-square test (with 1 df) of the (overall) difference between the two groups. Groups appear significantly different.

53 53 Caveats Survival estimates can be unreliable toward the end of a study when there are small numbers of subjects at risk of having an event.

54 WHI and breast cancer Small numbers left

55 55 Limitations of Kaplan-Meier Mainly descriptive Doesn’t control for covariates Requires categorical predictors Can’t accommodate predictor variables that change over time

56 56 Review question 2 Investigators studied a cohort of individuals who joined a weight-loss program by tracking their weight loss over 1 year. Which of the following statistical test is likely the most appropriate test for evaluating the effectiveness of the weight loss program? a. A two-sample t-test. b. ANOVA c. Repeated-measures ANOVA d. Chi-square e. Kaplan-Meier methods

57 57 Review question 3 Investigators compared mean cholesterol level between cases with heart disease and controls without heart disease. Which of the following is likely the most appropriate statistical test for this comparison? a. A two-sample t-test. b. ANOVA. c. Repeated-measures ANOVA d. Chi-square e. Kaplan-Meier methods

58 58 Review question 4 What is another way to analyze the data from review question 3? a. Logistic regression b. Cox regression c. Linear regression d. Kaplan-Meier methods e. There is no other way.

59 59 Review question 5 Which statement about this K-M curve is correct? a. The mortality rate was higher in the control group than the treated group. b. The probability of surviving past 100 days was about 50% in the treated group. c. The probability of surviving past 100 days was about 70% in the control group. d. Treatment should be recommended.

60 60 Introduction to Cox Regression Also called proportional hazards regression Multivariate regression technique where time-to-event (taking into account censoring) is the dependent variable. Estimates adjusted hazard ratios. A hazard ratio is a ratio of rates (hazard rates)

61 61 History “Regression Models and Life-Tables” by D.R. Cox, published in 1972, is one of the most frequently cited journal articles in statistics and medicine Introduced “maximum partial likelihood”

62 62 Distinction between hazard/rate ratio and odds ratio/risk ratio: Hazard ratio: ratio of rates Odds/risk ratio: ratio of proportions All are measures of relative risk! By taking into account time, you are taking into account more information than just binary yes/no. Gain power/precision. Logistic regression aims to estimate the odds ratio; Cox regression aims to estimate the hazard ratio Introduction to Cox Regression

63 63 Example 1: Study of publication bias By Kaplan- Meier methods From: Publication bias: evidence of delayed publication in a cohort study of clinical research projects BMJ 1997;315:640-645 (13 September)

64 64 From: Publication bias: evidence of delayed publication in a cohort study of clinical research projects BMJ 1997;315:640-645 (13 September) Table 4 Risk factors for time to publication using univariate Cox regression analysis Characteristic# not published# publishedHazard ratio (95% CI) Null29231.00 Non-significant trend 1640.39 (0.13 to 1.12) Significant47992.32 (1.47 to 3.66) Interpretation: Significant results have a 2-fold higher incidence of publication compared to null results. Univariate Cox regression

65 65 Example 2: Study of mortality in academy award winners for screenwriting Kaplan- Meier methods From: Longevity of screenwriters who win an academy award: longitudinal study BMJ 2001;323:1491-1496 ( 22-29 December )

66 Table 2. Death rates for screenwriters who have won an academy award. * Values are percentages (95% confidence intervals) and are adjusted for the factor indicated * Relative increase in death rate for winners Basic analysis37 (10 to 70) Adjusted analysis Demographic: Year of birth32 (6 to 64) Sex36 (10 to 69) Documented education39 (12 to 73) All three factors33 (7 to 65) Professional: Film genre37 (10 to 70) Total films39 (12 to 73) Total four star films40 (13 to 75) Total nominations43 (14 to 79) Age at first film36 (9 to 68) Age at first nomination32 (6 to 64) All six factors40 (11 to 76) All nine factors35 (7 to 70) HR=1.37; interpretation: 37% higher incidence of death for winners compared with nominees HR=1.35; interpretation: 35% higher incidence of death for winners compared with nominees even after adjusting for potential confounders

67 67 Characteristics of Cox Regression Can accommodate both discrete and continuous measures of event times Easy to incorporate time-dependent covariates—covariates that may change in value over the course of the observation period

68 68 Characteristics of Cox Regression, continued Cox models the effect of covariates on the hazard rate but leaves the baseline hazard rate unspecified. Does NOT assume knowledge of absolute risk. Estimates relative rather than absolute risk.

69 69 Assumptions of Cox Regression Proportional hazards assumption: the hazard for any individual is a fixed proportion of the hazard for any other individual Multiplicative risk

70 70 The Hazard function In words: the probability that if you survive to t, you will succumb to the event in the next instant.

71 71 The model Components: A baseline hazard function that is left unspecified but must be positive (=the hazard when all covariates are 0) A linear function of a set of k fixed covariates that is exponentiated. (=the relative risk) Can take on any form!

72 72 The model Proportional hazards: Hazard functions should be strictly parallel! Produces covariate-adjusted hazard ratios! Hazard for person j (eg a non-smoker) Hazard for person i (eg a smoker) Hazard ratio

73 73 The model: binary predictor This is the hazard ratio for smoking adjusted for age.

74 74 The model:continuous predictor Exponentiating a continuous predictor gives you the hazard ratio for a 1-unit increase in the predictor. This is the hazard ratio for a 10-year increase in age, adjusted for smoking.

75 75 Review Question 6 Exponentiating a beta-coefficient from linear regression gives you what? a. Odds ratios b. Risk ratios c. Hazard ratios d. None of the above

76 76 Review Question 7 Exponentiating a beta-coefficient from logistic regression gives you what? a. Odds ratios b. Risk ratios c. Hazard ratios d. None of the above

77 77 Review Question 8 Exponentiating a beta-coefficient from Cox regression gives you what? a. Odds ratios b. Risk ratios c. Hazard ratios d. None of the above

78 78 Intention-to-Treat Analysis in Randomized Trials Intention-to-treat analysis: compare outcomes according to the groups to which subjects were initially randomized, regardless of which intervention (if any) they actually followed.

79 79 Intention to treat Participants will be counted in the intervention group to which they were originally assigned, even if they: Refused the intervention after randomization Discontinued the intervention during the study Followed the intervention incorrectly Violated study protocol Missed follow-up measurements

80 80 Dietary Modification Trial <20% of diet from fat >=5 servings of fruit and vegetables >=6 servings of whole grains Primary outcomes: breast and colorectal cancer

81 81 Copyright restrictions may apply. Prentice, R. L. et al. JAMA 2006;295:629-642. Participant Flow in the Dietary Modification Component of the Women's Health Initiative

82

83 83 Why intention to treat? Preserves the benefits of randomization. Randomization balances potential confounding factors in the study arms. This balance will be lost if the data are analyzed according to how participants self-selected rather than how they were randomized. Simulates real life, where patients often don’t adhere perfectly to treatment or may discontinue treatment altogether Evaluates effectiveness, rather than efficacy

84 Copyright restrictions may apply. Prentice, R. L. et al. JAMA 2006;295:629-642. Baseline Demographics of Participants in Women's Health Initiative Dietary Modification Trial*

85 Benefits of randomization…

86 86 Copyright restrictions may apply. Prentice, R. L. et al. JAMA 2006;295:629-642. Nutrient Consumption Estimates and Body Weight at Baseline and Year 1

87 Real-world effectiveness… Only 31 percent of treatment participants got their dietary fat below 20% in the first year.

88 88 Effect of intention to treat on the statistical analysis Intention-to-treat analyses tend to underestimate treatment effects; increased variability due to switching “waters down” results.

89 Example Take the following hypothetical RCT: Treated subjects have a 25% chance of dying during the 2-year study vs. placebo subjects have a 50% chance of dying. TRUE RR= 25%/50% =.50 (treated have 50% less chance of dying) You do a 2-yr RCT of 100 treated and 100 placebo subjects. If nobody switched, you would see about 25 deaths in the treated group and about 50 deaths in the placebo group (give or take a few due to random chance).  Observed RR .50

90 90 Example, continued BUT, if early in the study, 25 treated subjects switch to placebo and 25 placebo subjects switch to control. You would see about 25*.25 + 75*.50 = 43-44 deaths in the placebo group And about 25*.50 + 75*.25 = 31 deaths in the treated group Observed RR = 31/44 .70 Diluted effect! (but not biased)

91 91 The researchers factored this into their power calculation… The study was powered to find a 14% difference in breast cancer risk between treatment and control. They assumed a 50% reduction in risk with perfect adherence, but calculated that this would translate to only a 14% reduction in risk with imperfect adherence.

92 92 Alternatives to ITT Per-protocol analysis Restricts analysis to only those who followed the assigned intervention until the end. Treatment-received analysis  Censored analysis: Subjects are dropped from the analysis at the time of stopping the assigned treatment  Transition analysis: e.g., controls who cross over to treatment contribute to the denominator for the control group until they cross over; then they contribute to the denominator for the treatment group. But becomes an observational study…

93 93 Review question 9 I randomized 600 people to receive treatment (n=300) or placebo (n=300). Of these, 10 treatment and 8 placebo subjects never started their study drug. An additional 30 dropped out of each group before the end of the trial (or were lost to followup). 18 treated subjects and 3 placebo subjects discontinued their treatment because of side effects. How many subjects do I include in my primary statistical analysis? a. 290 treatment, 292 placebo b. 272 treatment, 289 placebo c. 272 treatment, 292 placebo d. 242 treatment, 259 placebo e. 300 treatment, 300 placebo

94 94 Homework Finish reading textbook (if not already done!) Homework 9 Read intention-to-treat article (on Coursework) Review for the final exam


Download ppt "1 Tests for time-to-event outcomes (survival analysis)"

Similar presentations


Ads by Google